2区 · 医学
Article
作者: Girard, P.-M. ; Hocqueloux, L. ; Bauduin, C. ; Lhomme, E. ; Rieux, V. ; Lelièvre, J. D. ; Morlat, P. ; Fenwick, C. ; Thiébaut,, R. ; Pantaleo, G. ; Bouchaud, O. ; Lévy, Y. ; Guillaumat, L. ; Foucat, E. ; Richert, L. ; Boilet, V. ; Surenaud, M. ; Lacabaratz, C. ; Wiedemann, A. ; Molina, J.-M.
In this placebo-controlled phase II randomized clinical trial, we evaluated the safety and immunogenicity of a therapeutic prime-boost vaccine strategy using a recombinant DNA vaccine (GTU-MultiHIV B clade) followed by a boost vaccination with a lipopeptide vaccine (HIV-LIPO-5) in HIV-infected patients on combined antiretroviral therapy. We show here that this prime-boost strategy is well tolerated, consistently with previous studies in HIV-1-infected individuals and healthy volunteers who received each vaccine component individually.